Kristian Wachtell

List of Publications by Year in Descending Order

241 papers	12,937 citations	54 h-index	107 g-index
296 ext. papers	14,943 ext. citations	5 avg, IF	5.57 L-index

#	Paper	IF	Citations
241	Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.. *Reviews in Cardiovascular Medicine*, **2022**, 23, 95	3.9	0
240	Exercise-induced change in circulating NT-proBNP could not distinguish between patients with and without coronary artery disease: the CADENCE study.. *Scandinavian Cardiovascular Journal*, **2022**, 56, 107-113	2	
239	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet, The*, **2021**, 397, 1625-1636	40	101
238	Do Blockers Cause Depression?: Systematic Review and Meta-Analysis of Psychiatric Adverse Events During Blocker Therapy. *Hypertension*, **2021**, 77, 1539-1548	8.5	7
237	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. *Journal of Hypertension*, **2021**, 39, 1522-1545	1.9	7
236	Frequency and Impact of Hyponatremia on All-Cause Mortality in Patients With Aortic Stenosis. *American Journal of Cardiology*, **2021**, 141, 93-97	3	
235	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. *Lancet, The*, **2021**, 398, 1053-1064	40	27
234	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. *Circulation*, **2020**, 142, 621-642	16.7	88
233	On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy. *Blood Pressure*, **2020**, 29, 319-326	1.7	0
232	Medical Therapies for Heart Failure With Preserved Ejection Fraction. *Hypertension*, **2020**, 75, 23-32	8.5	25
231	Sudden cardiac death in asymptomatic patients with aortic stenosis. *Heart*, **2020**, 106, 1646-1650	5.1	5
230	Association of left bundle branch block with new onset abnormal wall motion in treated hypertensive patients with left ventricle hypertrophy: the LIFE Echo Sub-study. *Blood Pressure*, **2019**, 28, 84-92	1.7	
229	Rationale and design of DanGer shock: Danish-German cardiogenic shock trial. *American Heart Journal*, **2019**, 214, 60-68	4.9	82
228	High-sensitive cardiac Troponin T and exercise stress test for evaluation of angiographically significant coronary disease. *International Journal of Cardiology*, **2019**, 287, 1-6	3.2	4
227	Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study. *Blood Pressure*, **2019**, 28, 317-326	1.7	3
226	Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis. *American Journal of Cardiology*, **2019**, 124, 1736-1740	3	8
225	SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis. *Open Heart*, **2018**, 5, e000743	3	8

224	Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). *American Journal of Cardiology*, **2018**, 121, 739-745	3	17
223	Effect of simvastatin and ezetimibe on suPAR levels and outcomes. *Atherosclerosis*, **2018**, 272, 129-136	3.1	4
222	Antihypertensive Treatment With Blockade in Patients With Asymptomatic Aortic Stenosis and Association With Cardiovascular Events. *Journal of the American Heart Association*, **2017**, 6,	6	16
221	Pro-coagulant activity during exercise testing in patients with coronary artery disease. *Thrombosis Journal*, **2017**, 15, 3	5.6	5
220	Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study. *Blood Pressure*, **2017**, 26, 150-155	1.7	12
219	SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis. *Canadian Journal of Cardiology*, **2016**, 32, 1462-1469	3.8	7
218	Novel Trial Designs: Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE) Trial. *Current Cardiology Reports*, **2016**, 18, 11	4.2	29
217	Short and long-term survival after primary percutaneous coronary intervention in young patients with ST-elevation myocardial infarction. *International Journal of Cardiology*, **2016**, 203, 697-701	3.2	17
216	Acute myocardial infarction and lesion location in the left circumflex artery: importance of coronary artery dominance. *EuroIntervention*, **2016**, 12, 441-8	3.1	6
215	Increased hsCRP is associated with higher risk of aortic valve replacement in patients with aortic stenosis. *Scandinavian Cardiovascular Journal*, **2016**, 50, 138-45	2	6
214	A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. *Lancet, The*, **2016**, 388, 2665-2712	40	413
213	Assessing Optimal Blood Pressure in Patients With Asymptomatic Aortic Valve Stenosis: The Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS). *Circulation*, **2016**, 134, 455-68	16.7	24
212	Worsening diastolic function is associated with elevated fasting plasma glucose and increased left ventricular mass in a supra-additive fashion in an elderly, healthy, Swedish population. *International Journal of Cardiology*, **2015**, 184, 466-472	3.2	11
211	SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 355-67	2.5	6
210	Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. *Hypertension*, **2015**, 66, 368-73	8.5	49
209	suPAR: A New Biomarker for Cardiovascular Disease?. *Canadian Journal of Cardiology*, **2015**, 31, 1293-302	3.8	67
208	Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study. *Hypertension*, **2015**, 66, 945-53	8.5	19
207	Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study. *International Journal of Cardiology*, **2015**, 180, 122-8	3.2	8

206	Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). *American Journal of Cardiology*, **2015**, 116, 1840-4	3	21
205	Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. *Journal of Hypertension*, **2015**, 33, 2422-30	1.9	35
204	Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. *Journal of Hypertension*, **2015**, 33, 1480-6	1.9	11
203	Evaluation of Cardiac Damage in Hypertension: Electrocardiography **2015**, 3-12		1
202	High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy. *Open Heart*, **2015**, 2, e000152	3	6
201	Higher serum concentrations of N-terminal pro-B-type natriuretic peptide associate with prevalent hypertension whereas lower associate with incident hypertension. *PLoS ONE*, **2015**, 10, e0117864	3.7	7
200	Adipocytokines, C-reactive protein, and cardiovascular disease: a population-based prospective study. *PLoS ONE*, **2015**, 10, e0128987	3.7	29
199	Leisure-time physical inactivity and risk of myocardial infarction and all-cause mortality: a case-control study. *International Journal of Cardiology*, **2014**, 177, 599-600	3.2	2
198	Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study. *European Journal of Preventive Cardiology*, **2014**, 21, 330-8	3.9	15
197	Short- and long-term cause of death in patients treated with primary PCI for STEMI. *Journal of the American College of Cardiology*, **2014**, 64, 2101-8	15.1	221
196	Adjusting parameters of aortic valve stenosis severity by body size. *Heart*, **2014**, 100, 1024-30	5.1	18
195	Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. *Stroke*, **2014**, 45, 1939-46	6.7	17
194	Usefulness of the electrocardiogram in predicting cardiovascular mortality in asymptomatic adults with aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study). *American Journal of Cardiology*, **2014**, 114, 751-6	3	6
193	Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. *International Journal of Cardiology*, **2014**, 175, 492-8	3.2	24
192	Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). *Blood Pressure*, **2014**, 23, 206-12	1.7	22
191	Overweight, adipocytokines and hypertension: a prospective population-based study. *Journal of Hypertension*, **2014**, 32, 1488-94; discussion 1494	1.9	25
190	Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. *Journal of Hypertension*, **2014**, 32, 2472-8; discussion 2478	1.9	5
189	Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study). *PLoS ONE*, **2014**, 9, e101522	3.7	10

188	Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis. *Heart*, **2014**, 100, 28-33	5.1	40
187	A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. *European Journal of Preventive Cardiology*, **2014**, 21, 434-41	3.9	18
186	Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF. *Heart*, **2014**, 100, 1946-53	5.1	33
185	Five-year weight changes associate with blood pressure alterations independent of changes in serum insulin. *Journal of Hypertension*, **2014**, 32, 2231-7; discussion 2237	1.9	10
184	Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study. *Journal of Hypertension*, **2014**, 32, 667-72	1.9	14
183	Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. *American Journal of Hypertension*, **2014**, 27, 966-72	2.3	5
182	New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study. *Journal of the American Heart Association*, **2014**, 3, e000382	6	42
181	Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. *Circulation: Cardiovascular Imaging*, **2014**, 7, 422-9	3.9	71
180	Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. *International Journal of Cardiology*, **2013**, 166, 72-6	3.2	33
179	Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study. *Current Problems in Cardiology*, **2013**, 38, 365-409	17.1	18
178	Tertiary centres have improved survival compared to other hospitals in the Copenhagen area after out-of-hospital cardiac arrest. *Resuscitation*, **2013**, 84, 162-7	4	89
177	The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: a systematic review and meta-analysis. *International Journal of Cardiology*, **2013**, 167, 624-30	3.2	22
176	Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 243-51	6.4	44
175	Left atrial size and function as predictors of new-onset of atrial fibrillation in patients with asymptomatic aortic stenosis: the simvastatin and ezetimibe in aortic stenosis study. *International Journal of Cardiology*, **2013**, 168, 2322-7	3.2	26
174	Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 122-9	4.5	25
173	Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the LIFE study. *American Journal of Hypertension*, **2013**, 26, 567-73	2.3	17
172	Prognostic value of energy loss index in asymptomatic aortic stenosis. *Circulation*, **2013**, 127, 1149-56	16.7	91
171	Left atrial volume as predictor of valve replacement and cardiovascular events in patients with asymptomatic mild to moderate aortic stenosis. *Echocardiography*, **2013**, 30, 1008-14	1.5	10

170	Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. *Journal of Hypertension*, **2013**, 31, 2060-8	1.9	13
169	The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. *Journal of Atrial Fibrillation*, **2013**, 5, 789	0.8	15
168	The Electrocardiogram as a Risk Predictor in Asymptomatic Aortic Stenosis **2013**, 35-45		
167	A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis. *Heart*, **2012**, 98, 377-83	5.1	21
166	Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. *American Heart Journal*, **2012**, 163, 690-6	4.9	12
165	Global systolic load, left ventricular hypertrophy, and atrial fibrillation. *American Heart Journal*, **2012**, 164, e13	4.9	
164	Impact of QRS duration and morphology on the risk of sudden cardiac death in asymptomatic patients with aortic stenosis: the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study. *Journal of the American College of Cardiology*, **2012**, 59, 1142-9	15.1	30
163	Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. *American Journal of Hypertension*, **2012**, 25, 678-83	2.3	21
162	Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. *American Journal of Hypertension*, **2012** , 25, 1101-9	2.3	23
161	Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. *American Journal of Hypertension*, **2012**, 25, 1017-23	2.3	7
160	Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study. *Blood Pressure*, **2012**, 21, 6-11	1.7	12
159	Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. *Hypertension*, **2012**, 60, 347-53	8.5	50
158	Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. *Circulation*, **2012**, 125, 346-53	16.7	47
157	Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. *Journal of Hypertension*, **2012**, 30, 513-21	1.9	7
156	Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. *Journal of Hypertension*, **2012**, 30, 1252-9	1.9	7
155	Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. *Journal of Hypertension*, **2012**, 30, 1928-36	1.9	45
154	Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. *Journal of Hypertension*, **2011**, 29, 997-1004	1.9	4
153	In-treatment stroke volume predicts cardiovascular risk in hypertension. *Journal of Hypertension*, **2011**, 29, 1508-14	1.9	11

152	Differences in cardiovascular risk profile between electrocardiographic hypertrophy versus strain in asymptomatic patients with aortic stenosis (from SEAS data). *American Journal of Cardiology*, **2011**, 108, 541-7	3	22
151	Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction. *Circulation*, **2011**, 123, 887-95	16.7	242
150	Aortic root geometry in aortic stenosis patients (a SEAS substudy). *European Journal of Echocardiography*, **2011**, 12, 585-90		16
149	Response to Letters Regarding Article, Outcome of Patients With Low-Gradient Severe Aortic Stenosis and Preserved Ejection Fraction. *Circulation*, **2011**, 124,	16.7	1
148	Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study. *Journal of Human Hypertension*, **2011**, 25, 178-85	2.6	14
147	Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide--three new cardiovascular risk markers--do they improve risk prediction and influence treatment?. *Current Vascular Pharmacology*, **2010**, 8, 134-9	3.3	10
146	Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. *American Journal of Hypertension*, **2010**, 23, 845-51	2.3	24
145	Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. *Blood Pressure*, **2010**, 19, 145-51	1.7	
144	Risk prediction is improved by adding markers of subclinical organ damage to SCORE. *European Heart Journal*, **2010**, 31, 883-91	9.5	195
143	Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. *Journal of the American College of Cardiology*, **2010**, 55, 2299-307	15.1	306
142	Impact of pressure recovery on echocardiographic assessment of asymptomatic aortic stenosis: a SEAS substudy. *JACC: Cardiovascular Imaging*, **2010**, 3, 555-62	8.4	78
141	In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. *Blood Pressure*, **2010**, 19, 169-75	1.7	45
140	Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy). *Blood Pressure*, **2010**, 19, 140-4	1.7	27
139	Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). *Journal of Hypertension*, **2010**, 28, 377-83	1.9	44
138	Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. *Journal of Hypertension*, **2010**, 28, 1534-40	1.9	17
137	In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. *Journal of Hypertension*, **2010**, 28, 1541-6	1.9	33
136	Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. *American Journal of Cardiology*, **2010**, 105, 1802-8	3	48
135	Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). *American Journal of Cardiology*, **2010**, 106, 999-1005	3	31

134	Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). *American Journal of Cardiology*, **2010**, 106, 1634-9	3	27
133	New risk markers may change the HeartScore risk classification significantly in one-fifth of the population. *Journal of Human Hypertension*, **2009**, 23, 105-12	2.6	8
132	Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). *American Journal of Cardiology*, **2009**, 104, 1098-104	3	17
131	Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 306-12	4.5	22
130	Clustered metabolic abnormalities blunt regression of hypertensive left ventricular hypertrophy: the LIFE study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 634-40	4.5	26
129	Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. *American Heart Journal*, **2009**, 157, 177-84	4.9	11
128	Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. *JACC: Cardiovascular Imaging*, **2009**, 2, 390-9	8.4	162
127	Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2009**, 16, 242-8		20
126	Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). *Blood Pressure*, **2009**, 18, 180-6	1.7	9
125	Which markers of subclinical organ damage to measure in individuals with high normal blood pressure?. *Journal of Hypertension*, **2009**, 27, 1165-71	1.9	22
124	Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. *Journal of Hypertension*, **2009**, 27, 2351-7	1.9	29
123	Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. *Journal of Hypertension*, **2009**, 27, 567-74	1.9	21
122	Prevention of congestive heart failure in high risk patients. *European Heart Journal*, **2009**, 30, 638-9	9.5	2
121	Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy). *American Journal of Cardiology*, **2008**, 101, 510-5	3	58
120	Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study). *American Journal of Cardiology*, **2008**, 101, 1030-4	3	40
119	Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *New England Journal of Medicine*, **2008**, 359, 1343-56	59.2	1097
118	Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. *American Journal of Hypertension*, **2008**, 21, 273-9	2.3	16
117	Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). *European Journal of Echocardiography*, **2008**, 9, 809-15		116

116	Pre-discharge exercise test for evaluation of patients with complete or incomplete revascularization following primary percutaneous coronary intervention: a DANAMI-2 sub-study. *Cardiology*, **2008**, 109, 163-71	1.6	2
115	Does lowering cholesterol have an impact on the progression of aortic stenosis?. *Therapeutic Advances in Cardiovascular Disease*, **2008**, 2, 277-86	3.4	4
114	Is it time to change the definition of normal urinary albumin excretion?. *Nature Clinical Practice Nephrology*, **2008**, 4, 650-1		6
113	Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. *Hypertension*, **2008**, 51, 1109-14	8.5	79
112	Impact of the metabolic syndrome on the predictive values of new risk markers in the general population. *Journal of Human Hypertension*, **2008**, 22, 634-40	2.6	2
111	Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. *American Journal of Hypertension*, **2008**, 21, 701-7	2.3	5
110	Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. *Circulation: Arrhythmia and Electrophysiology*, **2008**, 1, 337-43	6.4	46
109	The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy. *Therapeutic Advances in Cardiovascular Disease*, **2008**, 2, 507-13	3.4	15
108	Left ventricular systolic performance in asymptomatic aortic stenosis. *Country Review Ukraine*, **2008** , 10, E16-E22		7
107	Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Journal of Hypertension*, **2008**, 26, 806-12	1.9	8
106	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. *Journal of Hypertension*, **2008**, 26, 1244-9	1.9	23
105	Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Journal of Hypertension*, **2008**, 26, 1472-6	1.9	13
104	Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. *Journal of Hypertension*, **2008**, 26, 26-34	1.9	32
103	Losartan versus atenolol on 24-hour ambulatory blood pressure. A LIFE substudy. *Blood Pressure*, **2007**, 16, 392-7	1.7	10
102	Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. *American Journal of Cardiology*, **2007**, 99, 970-3	3	125
101	Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myocardial Infarction-2 Substudy). *American Journal of Cardiology*, **2007**, 100, 937-43	3	3
100	The effect of angiotensin receptor blockers for preventing atrial fibrillation. *Current Hypertension Reports*, **2007**, 9, 278-83	4.7	1
99	Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. *Hypertension*, **2007**, 49, 311-6	8.5	168

98	Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. *Journal of Human Hypertension*, **2007**, 21, 625-32	2.6	43
97	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. *Circulation*, **2007**, 116, 700-5	16.7	163
96	N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. *European Heart Journal*, **2007**, 28, 1374-81	9.5	109
95	Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplasty. *European Heart Journal*, **2007**, 28, 407-14	9.5	20
94	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. *Journal of Hypertension*, **2007**, 25, 871-6	1.9	18
93	Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. *Journal of Hypertension*, **2007**, 25, 1079-85	1.9	18
92	Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. *American Journal of Hypertension*, **2007**, 20, 771-6	2.3	3
91	Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation. *Current Cardiology Reports*, **2006**, 8, 356-64	4.2	4
90	Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. *JAMA - Journal of the American Medical Association*, **2006**, 296, 1242-8	27.4	187
89	Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. *Hypertension*, **2006**, 47, 868-73	8.5	9
88	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. *Diabetes Care*, **2006**, 29, 595-600	14.6	88
87	Beat-to-beat QT dynamics in paroxysmal atrial fibrillation. *Heart Rhythm*, **2006**, 3, 660-4	6.7	14
86	Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. *Journal of Clinical Hypertension*, **2006**, 8, 169-73	2.3	5
85	N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. *Journal of Hypertension*, **2006**, 24, 1531-9	1.9	27
84	Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Journal of Hypertension*, **2006**, 24, 2079-84	1.9	15
83	Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. *Blood Pressure*, **2006**, 15, 198-206	1.7	8
82	High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. *Journal of Hypertension*, **2006**, 24, 655-61	1.9	32
81	Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. *Journal of Hypertension*, **2006**, 24, 775-81	1.9	62

80	The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. *Journal of Human Hypertension*, **2006**, 20, 460-4	2.6	1
79	Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a LIFE substudy. *Hypertension*, **2005**, 46, 492-9	8.5	25
78	QT dynamics in risk stratification after myocardial infarction. *Heart Rhythm*, **2005**, 2, 357-64	6.7	46
77	Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. *Blood Pressure*, **2005**, 14, 177-83	1.7	47
76	Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. *American Journal of Hypertension*, **2005**, 18, 1430-6	2.3	23
75	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *Journal of the American College of Cardiology*, **2005**, 45, 705-11	15.1	221
74	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *Journal of the American College of Cardiology*, **2005**, 45, 712-9	15.1	659
73	Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. *Journal of Hypertension*, **2005**, 23, 1083-90	1.9	31
72	Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. *Journal of Hypertension*, **2005**, 23, 891-8	1.9	46
71	Impairment of cardiac function in hypertensive patients with Type 2 diabetes: a LIFE study. *Diabetic Medicine*, **2005**, 22, 1005-11	3.5	15
70	Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. *Journal of Human Hypertension*, **2005**, 19, 301-7	2.6	31
69	Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). *American Journal of Cardiology*, **2005**, 95, 132-6	3	79
68	Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). *American Journal of Cardiology*, **2005**, 95, 280-3	3	6
67	Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy. *American Journal of Cardiology*, **2005**, 96, 1692-8	3	32
66	N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. *Hypertension*, **2005**, 46, 660-6	8.5	140
65	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. *Hypertension*, **2005**, 45, 198-202	8.5	436
64	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. *Circulation*, **2005**, 111, 1924-31	16.7	34
63	Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. *Hypertension*, **2005**, 45, 46-52	8.5	80

62	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. *Circulation*, **2004**, 110, 1456-62	16.7	379
61	Prognostic significance of left ventricular mass change during treatment of hypertension. *JAMA - Journal of the American Medical Association*, **2004**, 292, 2350-6	27.4	592
60	N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis. *European Journal of Heart Failure*, **2004**, 6, 313-7	12.3	47
59	Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. *Kidney International*, **2004**, S56-8	9.9	18
58	Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. *Journal of Human Hypertension*, **2004**, 18, 403-9	2.6	40
57	Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. *Journal of Human Hypertension*, **2004**, 18, 411-6	2.6	22
56	Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Journal of Human Hypertension*, **2004**, 18, 397-402	2.6	14
55	Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. *Journal of Human Hypertension*, **2004**, 18, 453-9	2.6	49
54	Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy. *Journal of Human Hypertension*, **2004**, 18, 375-80	2.6	4
53	Impact of valvular regurgitation on left ventricular geometry and function in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Journal of Human Hypertension*, **2004**, 18, 431-6	2.6	11
52	Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy. *Journal of Human Hypertension*, **2004**, 18, 445-52	2.6	31
51	24-h Ambulatory blood pressure in patients with ECG-determined left ventricular hypertrophy: left ventricular geometry and urinary albumin excretion-a LIFE substudy. *Journal of Human Hypertension* , **2004**, 18, 391-6	2.6	17
50	Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). *Journal of Human Hypertension*, **2004**, 18, 417-22	2.6	16
49	Usefulness of the assessment of the appropriateness of left ventricular mass to detect left ventricular systolic and diastolic abnormalities in absence of echocardiographic left ventricular hypertrophy: the LIFE study. *Journal of Human Hypertension*, **2004**, 18, 423-30	2.6	11
48	Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? A LIFE substudy. *Journal of Human Hypertension*, **2004**, 18, 437-43	2.6	6
47	Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). *American Journal of Cardiology*, **2004**, 94, 1076-80	3	21
46	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. *American Heart Journal*, **2004**, 148, 538-44	4.9	21
45	P-212: The effect of losartan versus atenolol on carotid atherosclerosis in the common carotid arteries in hypertension. Icarus, a life substudy. *American Journal of Hypertension*, **2004**, 17, S111	2.3	

44	N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. *Journal of Hypertension*, **2004**, 22, 1597-604	1.9	66
43	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. *Journal of Hypertension*, **2004**, 22, 1805-11	1.9	99
42	Albuminuria and Mortality in Hypertension. *Annals of Internal Medicine*, **2004**, 141, 245	8	1
41	Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. *Journal of Hypertension*, **2003**, 21, 781-7	1.9	65
40	Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. *Annals of Internal Medicine*, **2003**, 139, 901-6	8	376
39	Heart rate versus heart rate variability in risk prediction after myocardial infarction. *Journal of Cardiovascular Electrophysiology*, **2003**, 14, 168-73	2.7	49
38	Are left ventricular mass, geometry and function related to vascular changes and/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy. *Journal of Human Hypertension*, **2003**, 17, 305-11	2.6	12
37	Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. *American Heart Journal*, **2003**, 145, 919-25	4.9	30
36	Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. *Lancet, The*, **2003**, 362, 619-20	40	77
35	Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. *American Journal of Hypertension*, **2003**, 16, 180-6	2.3	8
34	Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. *Hypertension*, **2003**, 41, 75-82	8.5	33
33	Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). *American Journal of Cardiology*, **2002**, 89, 337-41	3	53
32	Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). *American Journal of Cardiology*, **2002**, 89, 399-402	3	14
31	A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction. *Journal of Human Hypertension*, **2002**, 16, 591-5	2.6	30
30	Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. *Circulation*, **2002**, 106, 227-32	16.7	70
29	Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Hypertension*, **2002**, 39, 739-43	8.5	176
28	Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Circulation*, **2002**, 105, 1071-6	16.7	154
27	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. *Journal of Hypertension*, **2002**, 20, 1445-50	1.9	63

26	Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. *Journal of Hypertension*, **2002**, 20, 405-12	1.9	123
25	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. *Journal of Hypertension*, **2002**, 20, 1879-86	1.9	271
24	Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. *Journal of Cardiac Failure*, **2002**, 8, 8-14	3.3	18
23	Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy. *Blood Pressure*, **2002**, 11, 285-92	1.7	8
22	Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. *American Heart Journal*, **2002**, 143, 319-26	4.9	107
21	Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. *American Heart Journal*, **2002**, 144, 530-7	4.9	45
20	Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. *American Heart Journal*, **2002**, 144, 1057-64	4.9	57
19	Vasodilatory capacity and vascular structure in long-standing hypertension: a LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. *American Journal of Hypertension*, **2002**, 15, 398-404	2.3	12
18	Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial. *American Journal of Hypertension*, **2002**, 15, A15	2.3	3
17	Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. *American Journal of Cardiology*, **2001**, 87, 54-60	3	65
16	Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. *Blood Pressure*, **2001**, 10, 74-82	1.7	97
15	Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. *American Heart Journal*, **2001**, 141, 784-91	4.9	60
14	Similar effects of isolated systolic and combined hypertension on left ventricular geometry and function: the LIFE Study. *American Journal of Hypertension*, **2001**, 14, 768-74	2.3	15
13	Endothelial dysfunction in resistance arteries is related to high blood pressure and circulating low density lipoproteins in previously treated hypertension. *American Journal of Hypertension*, **2001**, 14, 861-7	2.3	10
12	Maximal exercise capacity is related to cardiovascular structure in patients with longstanding hypertension. A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. *American Journal of Hypertension*, **2001**, 14, 1205-10	2.3	13
11	Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study. *Journal of Hypertension*, **2001**, 19, 127-34	1.9	41
10	Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. *Journal of Hypertension*, **2001**, 19, 1883-91	1.9	86
9	Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. *Journal of Hypertension*, **2000**, 18, 1129-38	1.9	60

8	Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study. Insulin Carotids US Scandinavia. *Journal of Hypertension*, **2000**, 18, 75-81	1.9	24
7	Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. *American Journal of Cardiology*, **2000**, 85, 466-72	3	140
6	Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. *Hypertension*, **2000**, 35, 6-12	8.5	200
5	Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. *American Heart Journal*, **1999**, 137, 1062-9	4.9	87
4	Time-varying serum uric acid predicts new-onset atrial fibrillation in treated hypertensive patients. The LIFE Study. *Exploration of Medicine*,128-138	1.1	0
3	Incident left bundle branch block predicts cardiovascular events and death in hypertensive patients with left ventricular hypertrophy. The LIFE Study. *Exploration of Medicine*,149-159	1.1	0
2	Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. *Exploration of Medicine*,139-148	1.1	0
1	Development of systolic dysfunction unrelated to myocardial infarction in treated hypertensive patients with left ventricular hypertrophy. The LIFE Study. *Exploration of Medicine*,160-172	1.1	0